Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China · Delayed Price · Currency is CNY 3.450
+0.020 (0.58%)
Jul 3, 2026, 3:04 PM CST
SHE:002581 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 283.27 | 274.74 | 355.66 | 425.78 | 356.18 | 397.44 |
Other Revenue | 0.07 | 0.07 | 4.75 | 4.01 | 0.9 | 5.27 |
| 283.34 | 274.81 | 360.41 | 429.79 | 357.08 | 402.71 | |
Revenue Growth (YoY) | -9.16% | -23.75% | -16.14% | 20.36% | -11.33% | 45.47% |
Cost of Revenue | 183.76 | 152.92 | 87.67 | 93.29 | 76.64 | 85.83 |
Gross Profit | 99.58 | 121.89 | 272.74 | 336.5 | 280.44 | 316.88 |
Selling, General & Admin | 244.67 | 269.38 | 336.65 | 453.3 | 426.21 | 477.76 |
Research & Development | 18.09 | 18.87 | 25.37 | 59.8 | 27.29 | 38.44 |
Other Operating Expenses | 6.04 | 6.1 | 6.31 | 6.78 | 6.24 | 6.83 |
Operating Expenses | 286.47 | 311.4 | 363.6 | 492.32 | 456.02 | 520.83 |
Operating Income | -186.89 | -189.51 | -90.86 | -155.81 | -175.57 | -203.95 |
Interest Expense | -1.12 | -1.12 | -0.18 | -9.06 | -9.41 | -6.88 |
Interest & Investment Income | 20.43 | 21.1 | 67.28 | 174.46 | 3.02 | 3.75 |
Earnings From Equity Investments | - | - | - | - | 217.45 | 471.94 |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | - | 0 | -0.01 |
Other Non Operating Income (Expenses) | 0.17 | 0.18 | 0.28 | -9.88 | 0.22 | -6.68 |
EBT Excluding Unusual Items | -167.41 | -169.35 | -23.49 | -0.29 | 35.72 | 258.18 |
Gain (Loss) on Sale of Investments | -8.66 | - | -18.65 | - | - | - |
Gain (Loss) on Sale of Assets | 3.89 | 3.77 | 1.16 | -6.33 | 0.05 | -0.15 |
Asset Writedown | -21.75 | -20.24 | -69.64 | -293.88 | -13.61 | -0.48 |
Legal Settlements | - | - | -33.27 | - | -15.49 | - |
Other Unusual Items | 10.09 | 10.28 | -2.29 | -12.76 | 6.05 | 21.05 |
Pretax Income | -183.83 | -175.53 | -146.18 | -313.25 | 12.72 | 278.6 |
Income Tax Expense | -14.63 | -14.7 | -3.34 | 8.89 | 13.58 | -0.09 |
Earnings From Continuing Operations | -169.2 | -160.83 | -142.84 | -322.14 | -0.86 | 278.69 |
Minority Interest in Earnings | 35.55 | 44.55 | 5.52 | -10.32 | -13.82 | -7.69 |
Net Income | -133.66 | -116.28 | -137.31 | -332.46 | -14.68 | 271 |
Net Income to Common | -133.66 | -116.28 | -137.31 | -332.46 | -14.68 | 271 |
Shares Outstanding (Basic) | 660 | 660 | 660 | 660 | 658 | 660 |
Shares Outstanding (Diluted) | 660 | 660 | 660 | 660 | 658 | 660 |
Shares Change (YoY) | -0.01% | -0.04% | 0.01% | 0.22% | -0.21% | -0.00% |
EPS (Basic) | -0.20 | -0.18 | -0.21 | -0.50 | -0.02 | 0.41 |
EPS (Diluted) | -0.20 | -0.18 | -0.21 | -0.50 | -0.02 | 0.41 |
Free Cash Flow | -414.88 | -433.43 | -15.56 | -40.82 | -85.95 | -106.86 |
Free Cash Flow Per Share | -0.63 | -0.66 | -0.02 | -0.06 | -0.13 | -0.16 |
Gross Margin | 35.14% | 44.36% | 75.67% | 78.30% | 78.54% | 78.69% |
Operating Margin | -65.96% | -68.96% | -25.21% | -36.25% | -49.17% | -50.64% |
Profit Margin | -47.17% | -42.31% | -38.10% | -77.35% | -4.11% | 67.29% |
Free Cash Flow Margin | -146.43% | -157.72% | -4.32% | -9.50% | -24.07% | -26.53% |
EBITDA | -150.18 | -151.92 | -49.7 | -87.43 | -110.63 | -144.38 |
EBITDA Margin | -53.00% | -55.28% | -13.79% | -20.34% | -30.98% | -35.85% |
D&A For EBITDA | 36.7 | 37.59 | 41.16 | 68.39 | 64.95 | 59.57 |
EBIT | -186.89 | -189.51 | -90.86 | -155.81 | -175.57 | -203.95 |
EBIT Margin | -65.96% | -68.96% | -25.21% | -36.25% | -49.17% | -50.64% |
Effective Tax Rate | - | - | - | - | 106.75% | - |
Revenue as Reported | 283.34 | 274.81 | 360.41 | 429.79 | 357.08 | 402.71 |